Celgene and Acceleration Pharma Announce Submission of Luspatercept Biologics License Application to FDA
pharmaceutical investing Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III ‘MEDALIST’ Study
